Skip to content

Total debt at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$9.78M-13.9%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$35.75M-32.5%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$250.82M+58.6%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$15.58M-82.6%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Calculated from Disc Medicine’s reported figures.

Plus components not separately reported this period.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's total debt?
Disc Medicine (IRON) reported total debt of $31.06M in Q1 2026.
How has Disc Medicine's total debt changed year-over-year?
Disc Medicine's total debt increased by 1.4% year-over-year, from $30.64M to $31.06M.
What is the long-term trend for Disc Medicine's total debt?
Over 5 years (2020 to 2025), Disc Medicine's total debt has grown at a 21.3% compound annual growth rate (CAGR), from $11.69M to $30.68M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.